Literature DB >> 2309578

Characterization of the latent transforming growth factor beta complex in bone.

J Pfeilschifter1, L Bonewald, G R Mundy.   

Abstract

Transforming growth factor beta (TGF-beta) is a 25 kD multifunctional polypeptide with pronounced effects on the proliferation and differentiation of a variety of cells in vitro. TGF-beta is a potent regulator of the activity of cells with the osteoblast phenotype and of isolated osteoclasts. It is released in increased amounts by bone cultures stimulated to resorb. Organ cultures of neonatal mouse calvaria produce TGF-beta as an inert large-molecular-weight complex that must be dissociated to release biologically active TGF-beta (5-8 ng/ml). We have shown recently that stimulated isolated avian osteoclasts release active TGF-beta from this bone-derived biologically latent form. In this report we have characterized this bone latent form of TGF-beta. Only small amounts of active TGF-beta (less than 0.5 ng/ml) and no free binding protein are detectable in conditioned medium from bone cultures. Active TGF-beta can be detected in acid-treated calvarial conditioned media in which none or only minute amounts could previously be detected. Following incubation at 37 degrees C, this activated TGF-beta gradually loses activity. Cross-linking studies using 125I-labeled TGF-beta show that this loss of activity is due to TGF-beta binding to a protein of approximately 300 kD. The TGF-beta latent complex accumulates in a linear manner and is stable in the presence of serum and the protease trypsin. Increases in temperature and pH extremes dissociate the complex to release active TGF-beta. Decreases in pH result in an exponential increase in TGF-beta activity. Significant activation of the latent TGF-beta was detectable at pH values as high as 4 and 5. Since the osteoclastic microenvironment is acidic during bone resorption, these data suggest that this acidic microenvironment may regulate TGF-beta activity by releasing active TGF-beta from its latent complex.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2309578     DOI: 10.1002/jbmr.5650050109

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  18 in total

Review 1.  The extracellular regulation of growth factor action.

Authors:  R Flaumenhaft; D B Rifkin
Journal:  Mol Biol Cell       Date:  1992-10       Impact factor: 4.138

2.  Enzymatic mineralization of hydrogels for bone tissue engineering by incorporation of alkaline phosphatase.

Authors:  Timothy E L Douglas; Philip B Messersmith; Safak Chasan; Antonios G Mikos; Eric L W de Mulder; Glenn Dickson; David Schaubroeck; Lieve Balcaen; Frank Vanhaecke; Peter Dubruel; John A Jansen; Sander C G Leeuwenburgh
Journal:  Macromol Biosci       Date:  2012-05-30       Impact factor: 4.979

3.  Ossifying fibroma tumor stem cells are maintained by epigenetic regulation of a TSP1/TGF-β/SMAD3 autocrine loop.

Authors:  Haiyan Qin; Cunye Qu; Takayoshi Yamaza; Ruili Yang; Xia Lin; Xue-Yan Duan; Kentaro Akiyama; Yi Liu; Qunzhou Zhang; Chider Chen; Yibu Chen; Hank Heng Qi; Xin-Hua Feng; Anh D Le; Songtao Shi
Journal:  Cell Stem Cell       Date:  2013-11-07       Impact factor: 24.633

Review 4.  Coupling factors involved in preserving bone balance.

Authors:  Beom-Jun Kim; Jung-Min Koh
Journal:  Cell Mol Life Sci       Date:  2018-12-04       Impact factor: 9.261

5.  Transforming growth factor-β in stem cells and tissue homeostasis.

Authors:  Xin Xu; Liwei Zheng; Quan Yuan; Gehua Zhen; Janet L Crane; Xuedong Zhou; Xu Cao
Journal:  Bone Res       Date:  2018-01-31       Impact factor: 13.567

Review 6.  Visions for the future in osteoporosis research.

Authors:  G R Mundy
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

7.  Modeling hepatic osteodystrophy in Abcb4 deficient mice.

Authors:  Katrin Hochrath; Sabrina Ehnert; Cheryl L Ackert-Bicknell; Yvonne Lau; Andrea Schmid; Marcin Krawczyk; Jan G Hengstler; Jordanne Dunn; Kanishka Hiththetiya; Birgit Rathkolb; Kateryna Micklich; Wolfgang Hans; Helmut Fuchs; Valérie Gailus-Durner; Eckhard Wolf; Martin Hrabě de Angelis; Steven Dooley; Beverly Paigen; Britt Wildemann; Frank Lammert; Andreas K Nüssler
Journal:  Bone       Date:  2013-03-29       Impact factor: 4.398

8.  Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth.

Authors:  Kyoko Takeuchi; Masahiro Abe; Masahiro Hiasa; Asuka Oda; Hiroe Amou; Shinsuke Kido; Takeshi Harada; Osamu Tanaka; Hirokazu Miki; Shingen Nakamura; Ayako Nakano; Kumiko Kagawa; Kenichiro Yata; Shuji Ozaki; Toshio Matsumoto
Journal:  PLoS One       Date:  2010-03-25       Impact factor: 3.240

9.  TGF-β1 as possible link between loss of bone mineral density and chronic inflammation.

Authors:  Sabrina Ehnert; Johannes Baur; Andreas Schmitt; Markus Neumaier; Martin Lucke; Steven Dooley; Helen Vester; Britt Wildemann; Ulrich Stöckle; Andreas K Nussler
Journal:  PLoS One       Date:  2010-11-22       Impact factor: 3.240

10.  Hyperinsulinemia reduces osteoblast activity in vitro via upregulation of TGF-β.

Authors:  Thomas Freude; Karl Friedrich Braun; Alexander Haug; Stefan Pscherer; Ulrich Stöckle; Andreas Klaus Nussler; Sabrina Ehnert
Journal:  J Mol Med (Berl)       Date:  2012-08-29       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.